In the setting of advanced and dedifferentiated thyroid cancer, the testing of genetic alterations in genes other than BRAF and RAS (virtually, easily evaluable in all molecular pathology laboratories) is acquiring an increasing importance. The gene discussed is BRAF; the disease is thyroid gland carcinoma.